Iconeus expands US presence to support growing adoption of fUS in preclinical brain imaging

Iconeus expands US presence, boosting functional ultrasound (fUS) adoption in preclinical brain imaging research.

Iconeus, a prominent innovator in functional ultrasound (fUS) technology for preclinical brain imaging, has significantly expanded its footprint in the United States. This strategic move aims to bolster the growing adoption of fUS across major research institutions, contract research organizations (CROs), and pharmaceutical companies. The expansion includes establishing a dedicated US entity and strengthening its sales and support infrastructure to better serve the North American market. Functional ultrasound is a revolutionary imaging modality that offers high-resolution, real-time visualization of brain activity and hemodynamics, providing critical insights into neurological disorders and therapeutic interventions. Unlike traditional imaging techniques, fUS boasts superior sensitivity and spatiotemporal resolution, making it an invaluable tool for studying complex brain functions in animal models. Iconeus's technology is particularly noted for its ability to provide quantitative measurements of cerebral blood volume changes, which correlate directly with neuronal activity. This capability is essential for researchers investigating conditions like Alzheimer's, Parkinson's, stroke, and epilepsy, as well as for evaluating the efficacy of new drug candidates. The increased presence will facilitate closer collaboration with US-based researchers, offering enhanced technical support, training, and rapid access to Iconeus's cutting-edge fUS systems. This expansion underscores the company's commitment to advancing neuroscience research globally and cementing fUS as a gold standard in preclinical neuroimaging. The move is expected to accelerate the development of new diagnostic and therapeutic strategies for brain diseases by empowering researchers with advanced tools to unravel brain complexities.